Skip to main content

Table 3 Evolution of the treatment response expressed by different standardised measures

From: Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

F/U (months) ACRpedi70 (%) ACRpedi90 (%) JADAS inactive (%) JADAS low activity (%) CID (%)
3 28.6 12.7 5.5 21.8 9.1
6 50.9 42.9 32.7 47.2 30.9
9 56.4 50.9 43.6 54.5 47.2
12 70.9 63.6 56.4 61.8 56.4
  1. F/U, Follow-up visit; CID, Clinically Inactive Disease [40]
  2. Results for 55 patients are shown. Patients who received biologics and/or who withdrew MTX were considered non-responders from the time point of starting the biologic or stopping MTX